Docoh
Loading...

MRNS Marinus Pharmaceuticals

GRANT
Utility
Ganaxolone for use in treatment of status epilepticus
7 Sep 21
This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid.
David Czekai, Maciej Gasior, Lorianne Masuoka, Julia Tsai, Joseph Hulihan, Alex Aimetti
Filed: 26 Feb 21
GRANT
Utility
Method of treatment using nanoparticulate ganaxolone formulations
27 Jul 21
In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.
Kenneth Shaw, Mingbao Zhang
Filed: 2 Oct 18
APP
Utility
Ganaxolone for Use In Treatment of Status Epilepticus
24 Jun 21
This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid.
David CZEKAI, Maciej GASIOR, Lorianne MASUOKA, Julia TSAI, Joseph HULIHAN, Alex AIMETTI
Filed: 26 Feb 21
GRANT
Utility
Methods of treating certain depressive disorders and delirium tremens
11 May 21
The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient.
Christopher Cashman, Jaakko Lappalainen, David A. Czekai
Filed: 25 Mar 20
APP
Utility
Injectable Neurosteroid Formulations Containing Nanoparticles
6 May 21
Mingbao Zhang, Raymond C. Glowaky, David Czekai
Filed: 13 Aug 20
GRANT
Utility
Injectable neurosteroid formulations containing nanoparticles
21 Sep 20
Mingbao Zhang, Raymond C. Glowaky, David Czekai
Filed: 13 Oct 16
APP
Utility
Methods of Treating Certain Depressive Disorders and Delirium Tremens
16 Sep 20
The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient.
Christopher Cashman, Jaakko Lappalainen, David A. Czekai
Filed: 24 Mar 20
APP
Utility
Ganaxolone for Use In Prophylaxis and Treatment of Pospartum Depression
10 Jun 20
Uses of ganaxolone in prophylaxis and treatment of postpartum depression are described.
Alex Aimetti, Christopher Cashman, Lorianne Masuoka, Jaakko Lappalainen
Filed: 5 Dec 19
GRANT
Utility
Methods of treating certain depressive disorders and delirium tremens
4 May 20
The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient.
Christopher Cashman, Jaakko Lappalainen, David A Czekai
Filed: 2 Oct 18
APP
Utility
Method of Administering a Neurosteroid to Effect Electroencephalographic (Eeg) Burst Suppression
23 Oct 19
The disclosure provides a method of eliciting electroencephalographic burst suppression or electroencephalographic suppression in a patient. the method includes administering to the patient a formulation comprising neurosteroid nanoparticles having a D50 of less than 2 microns and a polymeric surface stabilizer chosen from hydroxyethyl starch, dextran, and povidone and 0.1 to 50 mg of the neurosteroid per 1 kg of the patient's body weight The neurosteroid may be administered intravenously, intramuscularly, subcutaneously, or orally.
Michael SAPORITO, Albena PATRONEVA, David CZEKAI
Filed: 12 Oct 17
  • 1
Patents are sorted by USPTO publication date, most recent first